Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

1 Biotech Stock Set to Rebound in 2026

TheMotleyFool

0 0

1 Biotech Stock Set to Rebound in 2026Photo, wide shot, wide-angle lens, Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png

For all the enthusiasm around GLP-1s, also known as weight-loss drugs, Novo Nordisk (NYSE: NVO) tumbled nearly 42% in 2025. The once hot stock was confounded by headwinds, including rivals making progress in the weight-loss arena and the emergence of cheaper generics.

Fast-forward to 2026, and the stock is already shedding last year's bear market conditions. Shares of the maker of Wegovy are up 25% year to date. That's a new bull market and then some.

This weight-loss leader is already rebounding and could extend that bullishness this yea. Image source: Getty Images

Source Fool.com

Like: 0

NVO

Teilen